Goenaga Diana, Hampe Cornelia, Carré Nadège, Cailliau Katia, Browaeys-Poly Edith, Perdereau Dominique, Holt Lowenna J, Daly Roger J, Girard Jean, Broutin Isabelle, Issad Tarik, Burnol Anne-Françoise
Institut Cochin, Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 8104, Paris, France.
Mol Endocrinol. 2009 Jul;23(7):1043-51. doi: 10.1210/me.2008-0360. Epub 2009 Apr 9.
Grb14 belongs to the Grb7 family of molecular adapters and was identified as an inhibitor of insulin signaling. Grb14 binds to activated insulin receptors (IR) and inhibits their catalytic activity. To gain more insight into the Grb14 molecular mechanism of action, we generated various mutants and studied the Grb14-IR interaction using coimmunoprecipitation and bioluminescence resonance energy transfer (BRET) experiments. Biological activity was further analyzed using the Xenopus oocyte model and a functional complementation assay measuring cellular proliferation rate in Grb14 knockout mouse embryonic fibroblasts. These studies identified two important interaction sites, Grb14 L404-IR L1038 and Grb14 R385-IR K1168, involving the IR alphaC-helix and activation loop, respectively. Interestingly, the former involves residues that are likely to be crucial for the specificity of IR binding with regard to other members of the Grb7 family. In addition, mutation of the Grb14-S370 residue suggested that its phosphorylation status controlled the biological activity of the protein. We further demonstrated that insulin-induced Grb14-PDK1 interaction is required in addition to Grb14-IR binding to mediate maximal inhibition of insulin signaling. This study provides important insights into the molecular determinants of Grb14 action by demonstrating that Grb14 regulates insulin action at two levels, through IR binding and by interfering with downstream pathways. Indeed, a precise knowledge of the molecular mechanism of insulin signaling inhibition by Grb14 is a prerequisite for the development of insulin-sensitizing molecules to treat pathophysiological states such as obesity or type 2 diabetes.
Grb14属于分子衔接蛋白的Grb7家族,被鉴定为胰岛素信号传导的抑制剂。Grb14与活化的胰岛素受体(IR)结合并抑制其催化活性。为了更深入了解Grb14的分子作用机制,我们构建了各种突变体,并使用免疫共沉淀和生物发光共振能量转移(BRET)实验研究了Grb14与IR的相互作用。使用非洲爪蟾卵母细胞模型和功能互补试验测量Grb14基因敲除小鼠胚胎成纤维细胞的细胞增殖率,进一步分析了其生物学活性。这些研究确定了两个重要的相互作用位点,即Grb14的L404-IR的L1038和Grb14的R385-IR的K1168,分别涉及IR的αC螺旋和激活环。有趣的是,前者涉及的残基可能对于IR与Grb7家族其他成员结合的特异性至关重要。此外,Grb14的S370残基突变表明其磷酸化状态控制着该蛋白的生物学活性。我们进一步证明,除了Grb14与IR结合外,胰岛素诱导的Grb14与PDK1的相互作用对于介导胰岛素信号的最大抑制也是必需的。这项研究通过证明Grb14通过与IR结合以及干扰下游途径在两个水平上调节胰岛素作用,为Grb14作用的分子决定因素提供了重要见解。事实上,精确了解Grb14抑制胰岛素信号传导的分子机制是开发治疗肥胖症或2型糖尿病等病理生理状态的胰岛素增敏分子的先决条件。